Who
David K. Loomis
VP, Chief Accounting Officer
Company insider
Files Form 4 as: VP, Chief Accounting Officer, Arvinas.
In numbers
- Trades disclosed
- 20
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $122K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 8 Nov 2023
- Last trade
- 11 May 2026
- Last filed
- 13 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 May 2026filed 13 May 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $19K1,919 at $9.94 | filing |
| 11 May 2026filed 13 May 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $19K1,919 at $9.94 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —12,420 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,504 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,504 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —12,420 at $0.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $13K1,108 at $12.16 | filing |
| 23 Feb 2026filed 25 Feb 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $13K1,108 at $12.16 | filing |
| 13 Feb 2026filed 18 Feb 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $12K1,016 at $11.89 | filing |
| 13 Feb 2026filed 18 Feb 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $12K1,016 at $11.89 | filing |
| 7 Nov 2025filed 7 Nov 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $2,275230 at $9.89 | filing |
| 9 May 2025filed 13 May 2025 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,100 at $0.00 | filing |
| 9 May 2025filed 13 May 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —11,825 at $0.00 | filing |
| 24 Feb 2025filed 25 Feb 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $20K1,214 at $16.75 | filing |
| 13 Feb 2025filed 18 Feb 2025 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,176 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —10,584 at $0.00 | filing |
| 7 Nov 2024filed 12 Nov 2024 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $6,396231 at $27.69 | filing |
| 23 Feb 2024filed 27 Feb 2024 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,750 at $0.00 | filing |
| 23 Feb 2024filed 27 Feb 2024 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
| 8 Nov 2023filed 12 Nov 2024 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $3,904229 at $17.05 | filing |
News
Financial Comparison: Arvinas (NASDAQ:ARVN) & Geron (NASDAQ:GERN)ARVN · tickerreport.com · 20 Oct 2026Head to Head Comparison: Geron (NASDAQ:GERN) and Arvinas (NASDAQ:ARVN)ARVN · dailypolitical.com · 20 Oct 2026
0 headlines in the last 90 days name David K. Loomis; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.